Translations:Hyperlipidemia/9/ja: Difference between revisions

Latest revision as of 21:03, 13 April 2024

Information about message (contribute)

This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.

Message definition (Hyperlipidemia)

! Defect
! Increased lipoprotein
! Main symptoms
! Treatment
! Serum appearance
! Estimated prevalence
|-
!rowspan=3| [[Type I hyperlipoproteinemia|Type I]]
! [[Hyperlipoproteinemia type Ia|a]]
| {{OMIM|238600||none}}
| Buerger-Gruetz syndrome or familial hyperchylomicronemia
| Decreased [[lipoprotein lipase]] (LPL)
|rowspan=3| [[Chylomicrons]]
|rowspan=3| [[Acute pancreatitis]], [[lipemia retinalis]], eruptive skin [[xanthoma]]s, [[hepatosplenomegaly]]
|rowspan=3| Diet control
|rowspan=3| Creamy top layer
|rowspan=3| One in 1,000,000
|-
! [[hyperlipoproteinemia type Ib|b]]
| {{OMIM|207750||none}}
| Familial apoprotein CII deficiency
| Altered [[apolipoprotein C2|ApoC2]]
|-
! [[Hyperlipoproteinemia type Ic|c]]
| {{OMIM|118830||none}}
|
| [[Lipoprotein lipase|LPL]] inhibitor in blood
|-
!rowspan=2| Type II
! a
| {{OMIM|143890||none}}
| [[Familial hypercholesterolemia]]
| [[LDL receptor]] deficiency
| [[LDL]]
| [[Xanthelasma]], [[arcus senilis]], tendon xanthomas
| [[Bile acid sequestrant]]s, [[statin]]s, [[niacin (substance)|niacin]]
| Clear
| One in 500 for heterozygotes
|-
! b
| {{OMIM|144250||none}}
| Familial combined hyperlipidemia
| Decreased [[LDL receptor]] and increased [[apolipoprotein B|ApoB]]
| [[LDL]] and [[VLDL]]
|
| Statins, niacin, [[fibrate]]
| Turbid
| One in 100
|-
!colspan=2| Type III
| {{OMIM|107741||none}}
| [[Familial dysbetalipoproteinemia]]
| Defect in [[apolipoprotein E|Apo E 2]] synthesis
| [[Intermediate density lipoprotein|IDL]]
| Tuberoeruptive xanthomas and palmar xanthomas
| Fibrate, statins
| Turbid
| One in 10,000
|-
!colspan=2| Type IV
| {{OMIM|144600||none}}
| [[Familial hypertriglyceridemia]]
| Increased VLDL production and decreased elimination
| VLDL
|Can cause [[pancreatitis]] at high triglyceride levels
| Fibrate, niacin, statins
| Turbid
| One in 100
|-
!colspan=2| [[#type V|Type V]]
| {{OMIM|144650||none}}
|
| Increased VLDL production and decreased [[Lipoprotein lipase|LPL]]
| VLDL and chylomicrons
|
| Niacin, fibrate
| Creamy top layer and turbid bottom
|
|}

! 欠陥

 ! リポ蛋白質の増加
 ! 主な症状
 ! 治療
 ! 血清の外観
 ! 推定有病率

|-

 !rowspan=3| I型
 ! a
 |  238600
 | Buerger-Gruetz症候群または家族性高カイロミクロン血症
 | lipoprotein lipase/jaの減少 (LPL)
 |rowspan=3| Chylomicrons/ja
 |rowspan=3| Acute pancreatitis/ja, lipemia retinalis/ja, 発疹性皮膚黄色腫症, hepatosplenomegaly/ja
 |rowspan=3| 食事管理
 |rowspan=3| クリーミーなトップ層
 |rowspan=3| 100万分の1

|-

 ! b
 |  207750
 | 家族性アポ蛋白CII欠損症
 | 変化したApoC2

|-

 ! c
 |  118830
 |
 | 血中のLPL阻害

|-

 !rowspan=2| II型
 ! a
 |  143890
 | Familial hypercholesterolemia/ja
 | LDL receptor/ja欠乏症
 | LDL/ja
 | Xanthelasma/ja, arcus senilis/ja, 腱黄色腫
 | Bile acid sequestrant/ja, statin/ja, ナイアシン
 | クリア
 | ヘテロ接合体は500人に1人

|-

 ! b
 |  144250
 | 家族性複合高脂血症
 | LDL receptor/jaの減少とApoBの増加
 | LDL/jaとVLDL/ja
 |
 | スタチン, ナイアシン, fibrate/ja
 | 濁っている
 | 100人に1人

|-

 !colspan=2| III型
 |  107741
 | Familial dysbetalipoproteinemia/ja
 | Apo E 2合成の欠陥
 | IDL
 | 結節性黄色腫および手掌黄色腫
 | フィブラート, スタチン
 | 濁っている
 | 1万人に1人

|-

 !colspan=2| IV型
 |  144600
 | Familial hypertriglyceridemia/ja
 | VLDLの産生が増加し、排泄が減少する。
 | VLDL
 | トリグリセリド値が高いと膵炎を引き起こす可能性がある。
 | フィブラート, ナイアシン, スタチン
 | 濁っている
 | 100人に1人

|-

 !colspan=2| V型
 |  144650
 |
 | VLDL産生が増加し、LDLが減少する。
 | VLDLとカイロミクロン
 |
 | ナイアシン, フィブラート
 | 上層はクリーミーで、下層は濁っている。
 |

|}

Translations:Hyperlipidemia/9/ja: Difference between revisions

Latest revision as of 21:03, 13 April 2024

Navigation menu

Search